Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension

Guardado en:
Detalles Bibliográficos
Autores principales: Karine Briot, Rachel K Crowley, Maria Luisa Brandi, Stuart H Ralston, Han-Wook Yoo, Peter Kamenický, Takuo Kubota, Nobuaki Ito, Martine Cohen-Solal, Richard Keen, Angela Williams, Muhammad K Javaid, Hiroyuki Tanaka, Robin H Lachmann, Karl Insogna, Richard Eastell, Yasuhiro Takeuchi, Anthony A Portale, Thomas O Carpenter, Hae Ii Cheong, Yasuo Imanishi, Steven Ing, Suzanne Jan de Beur, Farzana Perwad, Pisit Pitukcheewanont, Thomas J Weber, Annabel Nixon, Mark Nixon, Erik A Imel
Formato: article
Lenguaje:EN
Publicado: BMJ Publishing Group 2021
Materias:
Medicine
R
Acceso en línea:https://doaj.org/article/1583f1afe5a54ea596b4387156690961
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares